Search
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalIn June 2005, the FDA issued a Not Approvable Letter for Zarnestra. … Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer.
NCX 1022
go.drugbank.com/drugs/DB05410ExperimentalNCX is an NO-releasing derivative of hydrocortisone.
AZD-8330
go.drugbank.com/drugs/DB06061InvestigationalAZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. … AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.
N-acetyl-alpha-neuraminic acid
go.drugbank.com/drugs/DB03721ExperimentalAn N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)
Synonyms: N-acetyl-alpha-neuraminic acid, N-Acetyl-alpha-D-neuraminic acidAminacrine
go.drugbank.com/drugs/DB11561InvestigationalIt is also used as an intracellular pH indicator.
Categories: Compounds used in a research, industrial, or household settingHGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalHGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.
rhIGFBP-3
go.drugbank.com/drugs/DB05897InvestigationalrhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models
Benzimate
go.drugbank.com/drugs/DB05170ExperimentalIt is currently under investigation by AmpliMed and is in phase I of clinical trial. … The anti-cancer and anti-viral activity of the benzimidazoles was originally investigated by the Proctor & Gamble Company beginning in the 1990's.
Nangibotide
go.drugbank.com/drugs/DB16247InvestigationalNangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).